Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines
- 120 Downloads
Angiotensin receptor blockers (ARBs) offer a new treatment alternative for patients with hypertension and heart failure. Due to comparatively high prices, most guidelines suggest ARBs be restricted to patients intolerant to angiotensin-converting enzyme inhibitors (ACEi). We analysed the prescribing patterns of ARBs in Sweden by combining prescription register data with patient self-reported data.
Survey data from 517 patients dispensed ARBs in 55 pharmacies and data on dispensed prescriptions from the Swedish Prescribed Drug Register were used to study indication, comorbidity and whether ARBs were initiated as first-line treatment.
In 2006, ARBs were dispensed to 3.6% of the Swedish population. The survey showed that 92% used them for hypertension. Register data showed that 23% of all patients initiated on an ARB had not been prescribed any other antihypertensive drugs 1 year prior to the initiation.
ARBs are commonly used in Sweden, mainly to treat hypertension. Adherence to prescribing guidelines may be improved.
KeywordsAngiotensin receptor blockers Drug utilisation Guidelines Prescribing ACE inhibitors Patient survey
The staff at the pharmacies involved in the survey are gratefully acknowledged for their participation. Andrejs Leimanis at the Centre for Epidemiology, National Board of Health and Welfare, Stockholm, Sweden, is gratefully acknowledged for part of the data analysis. Ulrika Benholm and Kristina Lönngren at the National Corporation of Swedish Pharmacies, Stockholm, Sweden, are gratefully acknowledged for their part in the study preparation. We also acknowledged Dr. Brian Godman, UK, for valuable comments.
The study was funded by the Swedish Pharmaceutical Benefits Board.
- 1.Kaplan W, Laing R (2004) Priority Medicines for Europe and the World Project. A Public Health Approach to Innovation. WHO, Geneva. Retrieved on 2008.07.21 from http://whqlibdoc.who.int/hq/2004/WHO_EDM_PAR_2004.7.pdf.
- 5.Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115–1140PubMedCrossRefGoogle Scholar
- 10.Swedish Council on Technology Assessment in Health Care (SBU) (2004) Moderately Elevated Blood Pressure. SBU report 170. Stockholm. Retrieved on 2008.04.18 from http://www.sbu.se/en/Published/Yellow/Moderately-Elevated-Blood-Pressure/
- 11.Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B et al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776PubMedCrossRefGoogle Scholar
- 14.Fletcher AE, Palmer AJ, Bulpitt CJ (1994) Cough with angiotensin converting enzyme inhibitors: how much of a problem? J Hypertens Suppl 12:S43–S47Google Scholar
- 15.Pharmaceutical Benefits Board price database, http://www.lfn.se
- 17.Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 112:e154–e235PubMedCrossRefGoogle Scholar
- 22.World Health Organization (WHO) (2007) Guidelines for ATC classification and DDD assignment. WHO Collaborationg Center for Drug Statistics Methodology, Oslo, www.whocc.no
- 23.World Health Organization (WHO) (2003) Introduction to Drug Utilisation Research, NLM classification WB 330, OsloGoogle Scholar
- 26.Strom B (2005) Pharmacoepidemiology, 4th edn. John Wiley and Sons, ChichesterGoogle Scholar
- 36.Swedish Pharmaceutical Benefits Board (LFN) (2008) Summary: A review of medicines for lowering blood pressure. Stockholm. Retrieved on 2008.04.18 from http://www.lfn.se/LFNTemplates/Page____1779.aspx